EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Yoshiki Kasagi, Naomichi Okamoto iD, Reiji Yoshimura iD

Psychiatry and Clinical Neurosciences Reports · 2026-06 · 5 (2)

DOI: 10.1002/pcn5.70334 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Psychiatry and Clinical Neurosciences Reports, online erschienen am 17.04.2026. Verfasst von Yoshiki Kasagi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry University of Occupational and Environmental Health Kitakyushu Fukuoka Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent agitation and aggression despite antipsychotic therapy. Valproate augmentation (800 mg/day) improved irritability and psychomotor agitation but was complicated by hypoglycemia, suggestive of relative carnitine deficiency, and subsequent pancytopenia. Both adverse events resolved after discontinuation. Behavioral symptoms markedly worsened following withdrawal. Clozapine and electroconvulsive therapy were declined. Lithium augmentation (600 mg/day; serum level 0.8 mEq/L) was initiated, resulting in improvement of dangerous behaviors and agitation. The Brief Psychiatric Rating Scale total score improved from 80 to 64, particularly in the hostility and excitement items. No readmission to the psychiatric ward occurred during a 3‐month follow‐up.

Conclusion

This case highlights the clinical dilemma of mood stabilizer augmentation in residual‐phase schizophrenia. While valproate demonstrated behavioral efficacy, serious adverse events necessitated its discontinuation. Lithium may represent a potential alternative for managing aggression and agitation, but further research is warranted.

Schlagwörter

Stichwörter der Autor:innen

lithiummood stabilizerresidual phaseschizophreniavalproic acid

Autor:innen und Institutionen

  • Department of Psychiatry University of Occupational and Environmental Health Kitakyushu Fukuoka Japan.

ORCID-Profile: Naomichi Okamoto, Reiji Yoshimura

Zitieren

APA

Kasagi, Y., Okamoto, N., & Yoshimura, R. (2026). Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response. Psychiatry and Clinical Neurosciences Reports, 5(2). https://doi.org/10.1002/pcn5.70334

Vancouver

Kasagi Y, Okamoto N, Yoshimura R. Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response. Psychiatry and Clinical Neurosciences Reports. 2026;5(2). doi:10.1002/pcn5.70334

BibTeX
@article{Kasagi2026,
  author = {Kasagi, Yoshiki and Okamoto, Naomichi and Yoshimura, Reiji},
  title = {Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response},
  journal = {Psychiatry and Clinical Neurosciences Reports},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.1002/pcn5.70334}
}
Kostenlos starten →